FDA’s Generics Office Loses Another Director As Geba Makes Quick Exit
This article was originally published in The Pink Sheet Daily
Executive Summary
Gregory Geba will step down March 15, saying ongoing organizational changes created challenges to implementing his vision; CDER Director Janet Woodcock will run the office during the nationwide search for a replacement.
You may also be interested in...
US FDA Again Looks Outside Generic Drugs Office For New Director
Sally Choe, who has been working in the Office of Translational Sciences, will take over for Kathleen Uhl in March.
Generics Office At US FDA Could Get New Director Before Uhl Departs
Kathleen Uhl gave seven months' notice of her retirement, which may allow new director to be hired and on-boarded before she departs.
2013’s Most Notable Stories In “The Pink Sheet” DAILY
FDA budget challenges, biosimilars, R&D revamps and social media are among stories from the past year that captured the attention of readers and reflect major biopharma trends.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports
New to Pink Sheet?
Start a free trial today!
Register for our free email digests:
Register for our free email digests: